The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug–induced apoptosis
Open accessAbstract
Multiple myeloma remains an incurable disease. One of the major problems is that myeloma cells develop drug resistance on interaction with bone marrow stromal cells. In this study, we examined the effects of macrophages (Mφs), a type of stromal cells, on myeloma cell survival and response to chemotherapy. We showed that Mφ, in particular tumor-associated Mφ, is a protector of myeloma cells. The protective effect was dependent on direct contact between Mφs and myeloma cells. Mφs protected both myeloma cell lines and primary myeloma cells from spontaneous and chemotherapy drug-induced apoptosis by attenuating the activation and cleavage of caspase-dependent apoptotic signaling. These findings are clinically relevant because we found that CD68+ Mφs heavily infiltrate the bone marrow of patients with myeloma but not the bone marrow of control patients. Thus, our results indicate that Mφs may contribute to myeloma cell survival and resistance to chemotherapeutic treatment in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Cited by
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484
More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis
Gschwandtner, M., Derler, R., & Midwood, K. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02759 · Cited by 611
Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., & Clements, V. K. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.011 · Cited by 583
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Zavidij, O., Haradhvala, N. J., Mouhieddine, T. H., Sklavenitis-Pistofidis, R., Cai, S., Reidy, M., Rahmat, M., Flaifel, A., Ferland, B., Su, N. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0053-3 · Cited by 374
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Targeting inflammasome/IL-1 pathways for cancer immunotherapy
Guo, B., Fu, S., Zhang, J., Liu, B., & Li, Z. (2016) · Scientific Reports · doi:10.1038/srep36107 · Cited by 302
Overdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501351 · Cited by 297
Weizman, N., Krelin, Y., Shabtay-Orbach, A., Amit, M., Binenbaum, Y., Wong, R. J., & Gil, Z. (2014) · Oncogene · doi:10.1038/onc.2013.357 · Cited by 281
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
García-Ortiz, A., Rodríguez-García, Y., Encinas, J., Maroto-Martín, E., Castellano, E., Teixidó, J., & Martínez-López, J. (2021) · Cancers · doi:10.3390/cancers13020217 · Cited by 238
Wang, X., Li, C., Ju, S., Wang, Y., Wang, H., & Zhong, R. (2011) · Leukemia & Lymphoma · doi:10.3109/10428194.2011.591004 · Cited by 103
Hofbauer, D., Mougiakakos, D., Broggini, L., Zaiss, M., Büttner-Herold, M., Bach, C., Spriewald, B., Neumann, F., Bisht, S., Nolting, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.002 · Cited by 100
Pang, J., Shi, Q., Liu, Z., He, J., Liu, H., Lin, P., Cui, J., & Yang, J. (2017) · Haematologica · doi:10.3324/haematol.2016.154062 · Cited by 57
Self-citationBone marrow inflammation in haematological malignancies
de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01003-x · Cited by 54
Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFα
Akhmetzyanova, I., Aaron, T., Galbo, P., Tikhonova, A., Dolgalev, I., Tanaka, M., Aifantis, I., Zheng, D., Zang, X., & Fooksman, D. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005327 · Cited by 39
Shen, X., Guo, Y., Yu, J., Qi, J., Shi, W., Wu, X., Ni, H., & Ju, S. (2016) · Clinical and Experimental Medicine · doi:10.1007/s10238-015-0355-4 · Cited by 37
The multi-faceted potential of CD38 antibody targeting in multiple myeloma
Shallis, R. M., Terry, C. M., & Lim, S. H. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1990-2 · Cited by 20
Metadata
- Authors
- Zheng, Y., Cai, Z., Wang, S., Zhang, X., Qian, J., Hong, S., Li, H., Wang, M., Yang, J., & Yi, Q.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-10-22
- Volume
- 114
- Issue
- 17
- Pages
- 3625-3628
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2033393138
- Cited by
- 307
- References
- 1
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
